CNS activity of alectinib: pooled analysis of phase II studies after
progression on crizotinib
Gadgeel, et al, J Clin Oncol 2016 34(34): 4079–85
Pooled population
(n=225)
Patients with CNS disease at baseline, n (%)
136 (60)
Median age, years (range)
< 65, n (%)
≥65, n (%)
50.9 (22–75)
123 (90)
13 (10)
Gender, n (%)
Male
Female
58 (43)
78 (57)
Prior chemotherapy, n (%)
Yes
No
109 (80)
27 (20)
Median time since last dose of crizotinib, days (range)
15.0 (7– 676)
Radiation therapy, n (%)
No prior brain radiation
Prior brain radiation
41 (30)
95 (70)
Within 4 weeks of start of alectinib
> 4 weeks to ≤6 months before start of alectinib
> 6 months before start of alectinib
7 (5)
33 (24)
55 (40)
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
